The role of splenectomy in myelofibrosis with myeloid metaplasia

Minerva Chirurgica

Volumn 65, Issue 6, 2010, Pages 619-625

  Barugola, G ^a   Cavallini, A ^a   Lipari, G ^a   Armatura, G ^a   Mantovani, W ^b   Baggio, E ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Liver diseases; Primary myelofibrosis; Splenectomy

Indexed keywords

ARTICLE; HUMAN; MIDDLE AGED; MYELOID METAPLASIA; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SPLENECTOMY;

HUMANS; MIDDLE AGED; PRIMARY MYELOFIBROSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SPLENECTOMY;

EID: 79953175253     PISSN: 00264733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Cabot EB, Brennan MF, Rosenthal DS, Wilson RE. Splenectomy in myeloid metaplasia. Ann Surg 1978; 187: 24-9.
2. Barosi G, Ambrosetti A, Buratti A, Finelli C, Liberato NL, Quaglini S et al. Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction. Leukemia 1993; 7: 200-6. (Pubitemid 23079228)
3. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76. (Pubitemid 23073154)
4. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA 1982; 247: 2543-6. (Pubitemid 12155954)
5. Mulder H, Steenbergen J, Haanen C. Clinical Course and Survival after Elective Splenectomy in 19 Patients with Primary Myelofibrosis. Br J Haematol 1977; 35: 419-26.
6. Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A. Palliative goals, patient selection, and perioperative platelet management:outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006; 107: 361-70. (Pubitemid 44036566)
7. Rondelli D, Barosi G, Bacigalupo A, Prchal JT, Popat U, Alessandrino EP et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005; 105: 4115-9. (Pubitemid 40656163)
8. Mesa RA. Myelofibrosis with myeloid metaplasia: therapeutic options in 2003. Curr Hematol Rep 2003; 2: 264-70.
9. Li Z, Deeg HJ. Pros and cons of splenectomy in patiets with myelofibrosis undergoing stem cell trasplantaron. Leucemia 2001; 15: 465-7. (Pubitemid 32243782)
10. Jarvinene H, Kivilaakso E, Ikkala E, Vuopio P, Hastbacka J. Splenectomy for myelofibrosis. Ann Clin Res 1982; 14: 66-71. (Pubitemid 12074812)
11. Elliott MA, Chen MG, Silverstein MN, Tefferi A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Blood 1997; 90(Suppl 1): 346.
12. Tefferi A, Jimenez T, Gray LA, Mesa RA, Chen MG. Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia. Eur J Haematol 2001; 66: 37-42. (Pubitemid 32099408)
13. Benbassat J, Gilon D, Penchas S. The choice between splenectomy and medical treatment in patients with advanced agnogenic myeloid metaplasia. Am J Haematol 1990; 33: 128-35. (Pubitemid 20040090)
14. Faoro LN, Tefferi A, Mesa RA. Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia. Eur J Haematol 2005; 74: 117-20. (Pubitemid 40175314)
15. Carrol BJ, Phillips EH, Semel CJ, Fallas M, Morgenstern L. Laparoscopic splenectomy. Surg Endoscopy 1992; 6: 183-5.
16. Decher G, Millet B, Guillon F, Atger J, Linen M. Laparoscopic splenectomy for benign and malignant haematologic diseases: 35 consecutive cases. World J Surg 1998; 22: 62-8. (Pubitemid 28028002)
17. Gigot JF, Healy ML, Ferrant A, Michaux JL, Njnou B, Kestin PJ. Laparoscopic splenectomy in adults and children: experience with 31 patients. Surgery 1996; 119: 384-9. (Pubitemid 26115830)
18. Akpek G, McAneny D, Weintraub L. Risks and benefits of splenectomy in myelofibrosis with myeloid metaplasia: a retrospective analysis of 26 cases.) Surg Oncol 2001; 77: 42-8. (Pubitemid 32382018)
19. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 1999; 17: 2954-70. (Pubitemid 29415257)
20. Barosi G, Ambrosetti A, Centra A, Falcone A, Finelli C, Foa P et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. Blood 1998; 91: 3630-6. (Pubitemid 28225729)
21. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000; 95: 2226-33. (Pubitemid 30167718)
22. Cervantes F, Barosi G, Boluda JCH, Marccheti M. Myelfibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival. Eur J Haematol 2001; 66: 324-27. (Pubitemid 32552167)
23. Arnoletti JP, Karam J, Brodsky J. Early prospective complications of splenectomy for hematologic disease. Am J Clin Oncol 1999; 22: 114-8. (Pubitemid 30263335)
24. Mesa RA. Myelofibrosis with myeloid metaplasia: therapeutic options in 2003. Curr Hematol Rep 2003; 2: 264-70.
25. Beitz J, Gnecco C, Justice R. Quality-of-life end points in cancer clinical trials: the U.S. Food and Drug Administration perspective. J Natl Cancer Inst Monogr 1996: 7-9.
26. McAnemy D, La Morte WW, Scott TE, Weintraub LR, Beauley RM. Is splenectomy more dangerous for massive spleens? Am J Surg 1998; 175: 102-107. (Pubitemid 28132898)
27. Mesa RA, Tefferi A. Palliative splenectomy in myelofibrosis with myeloid metaplasia. Leuk Lymphoma 2001;42:901-11. (Pubitemid 32827512)